Third quarter sales of Novo’s in-demand obesity drug totaled $2.5 billion, roughly 81% higher than the same period in 2023 ...

Novo Nordisk is lifting curbs on prescriptions of its weight-loss drug Wegovy in the United States and is increasing supply ...

Novo Nordisk reported forecast-beating third-quarter sales of its popular Wegovy weight-loss drug on Wednesday, reassuring ...

Following a disappointing earnings showing from Eli Lilly last week, Novo Nordisk’s latest report on the performance of its ...

The company narrowed its full-year guidance as its blockbuster weight-loss drug soars in popularity.

Sales of Novo Nordisk’s obesity drug Wegovy were 81% higher in the third quarter of 2024 than the same period last year amid loosening supply constraints and broader insurance coverage ...

Since Wegovy is a prescription medication, your insurance coverage may affect your ability to get the drug at an affordable cost. The status of the supply chain can also determine how accessible ...

It is a sign that Novo Nordisk’s efforts to ramp up the supply of those drugs are starting to pay off, as demand continues to ...

Less than a month after the FDA removed Eli Lilly’s tirzepatide from its shortage list, the agency has done the same for Novo Nordisk’s rival GLP-1 semaglutide, potentially signaling the end of a d | ...

On Wednesday, Novo Nordisk A/S (NYSE:NVO) reported third-quarter 2024 sales of 71.311 billion Danish kroner (around $10.3 ...

Novo Nordisk on Wednesday reported third quarter earnings broadly in line with expectations and narrowed its 2024 full-year ...

Both Ozempic and Wegovy are forms of semaglutide ... the demand or projected demand for semaglutide within the United States ...